Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

152.55

+3.56 (2.39%)

as of Aug 21, 2026, 8:00:00 pm Market Open.

311 watching

Investor Insights

Aug 22, 2026, 12:00 am

This summary was created by AI, based on 25 opinions in the last 12 months.

Merck & Company (MRK) remains a focal point in the pharmaceutical sector, particularly due to its leading cancer treatment drug, Keytruda, which accounts for a significant portion of its revenue but faces a patent expiration in 2028. Experts note that while revenue growth has been modest in the past few years, recent breakthroughs in cancer trials have generated optimism for the company's potential future. There is a general recognition of Merck's strong pipeline of upcoming drugs, which could help offset the revenue decline anticipated from Keytruda going off-patent. Several experts have recommended strict stop-loss strategies to protect investments while pursuing gains, emphasizing a balance of growth potential and valuation concerns. Overall, the sentiment leans towards cautious optimism as analysts grapple with Merck's future amidst challenges and opportunities.

Consensus

positive

Valuation

fair value

Similar

Pfeizer, PFE

DON'T BUY

Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.

Wealthica Track your Stocks in your Watch List

BUY

Pharmaceutical stocks in the US have been absolutely decimated. Dirt cheap. Generates a ton of free cash flow.

BUY

An equally good stock as Pfizer (PFE-N) at these levels. 4.5% yield. Always have good products. Going through a difficult spell right now.

BUY

Great valuation and a good entry point.

DON'T BUY

Would prefer Pfizer (PFE-N) which has a far superior pipeline.

BUY

Big issue has been VIOXX. Very convoluted over the near term as to what will happen. Don't know what the legal issues will be. There could be more bad news from previous users of the drug. Have lots of money. Trades at almost 20% discount to the peer group. Nearly 5% yield. Has room for upside. Won't be an easy road.

WEAK BUY

Thinks it's going to be very tough to legally get this company with VIOXX. They have it as the 11th position in their portfolio. Model price is $38. Prefers Pfizer which has a bigger upside.

WEAK BUY

Feels they should have re-labelled rather than pulling Vioxx so that people would know how to use them properly. A huge number of lawsuits they could face down the road. Didn't grow by acquisition, so their pipeline looks a bit murky. A great company and will be around for a long time.

DON'T BUY

Companies like Pfizer and Merck have been coming apart for quite awhile. Growth rate has gone from 30% to low single digits. When this happens, the P/E has to contract. There are more sellers than buyers. One of the few that is doing better is Schering AG. Growth rate is accelerating and have a good line up of drugs.

DON'T BUY

Facing a large number of large and messy law suits.

WEAK BUY

Mispriced. Expects that down the road Vioxx will come back.

DON'T BUY

A cockroach company with one problem after another coming out of the woodwork.

DON'T BUY

In 2002, 2003 and early 2004 the chart looked like it was going to hold, but then collapsed. A broken down stock. Usually takes a significant amount of time for the news to be absorbed.

DON'T BUY

More aggressive than what they would want. A number of outstanding issues regarding litigation would keep the top executives eyes off running the business. Prefers Pfizer.

DON'T BUY

Market is pricing in $20/25 million for class action law suits, but it could be more. Would need a tremendous amount of earnings growth to reach what people are expecting and this is unlikeley. High dividend yield. No longer a safe story.

Showing 241 to 255 of 310 entries

Most Recent Experts

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Darren Sissons

Campbell Lee & Ross

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Merck & Company (MRK)